Cargando…
Durable benefit and change in TCR clonality with nivolumab in a Lynch syndrome–associated glioma
Germline replication-repair deficient (gRRD) gliomas are exceptional events, and only a few of them have been treated with immune checkpoint inhibitors (ICIs). Contrary to sporadic gliomas, where ICIs have failed to show any objective benefit, the very few patients with gRRD gliomas treated with ICI...
Autores principales: | Cabezas-Camarero, Santiago, Pérez-Alfayate, Rebeca, García-Barberán, Vanesa, Polidura, María Carmen, Gómez-Ruiz, María Natividad, Casado-Fariñas, Isabel, Subhi-Issa, Issa Ahmad, Hernández, José Carlos Plaza, Garre, Pilar, Díaz-Millán, Isabel, Pérez-Segura, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185004/ https://www.ncbi.nlm.nih.gov/pubmed/35694191 http://dx.doi.org/10.1177/17588359221100863 |
Ejemplares similares
-
Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022) -
Lung Adenocarcinoma with Lynch Syndrome and the Response to Nivolumab
por: Kawashima, Yosuke, et al.
Publicado: (2019) -
Glioblastoma: an organ-confined disease?
por: Cabezas-Camarero, Santiago, et al.
Publicado: (2022) -
Quantification of HTLV-1 Clonality and TCR Diversity
por: Laydon, Daniel J., et al.
Publicado: (2014) -
Pitfalls in TCR gene clonality testing: teaching cases
por: Groenen, Patricia J. T. A., et al.
Publicado: (2008)